

Correction to “Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Guidelines on Model Fitting and Recommendations on Time Course for In Vitro CYP Induction Studies Including Impact on Drug Interaction Risk Assessment”

In the above article [Wong SG, Ramsden D, Dallas S, Fung C, Einolf HJ, Palamanda J, Chen L, Goosen TC, Siu YA, Zhang G, Tweedie D, Hariparsad N, Jones B, and Yates PD (2021) *Drug Metab Dispos*, **49**: 94-110; DOI: <https://doi.org/10.1124/dmd.120.000055>], the three pairs of summary rows [“Overall AFE (*n*)” and “% Within 2-fold (*n*)”] in Table 3 were accidentally duplicated. The corrected Table 3 is provided below.

TABLE 3

Summary of AFE comparing E_{max} , EC_{50} , or E_{max}/EC_{50} at earlier time points (6, 12, 24, or 48) to 72 h

AFE's were summarized for each cytochrome P450 isoform and respective inducers: CYP1A2 (omeprazole, phenobarbital), CYP2B6 (efavirenz, phenobarbital, rifampicin), CYP2C9 (rifampicin), CYP3A4 (efavirenz, rifampicin). ND: Not determined.

AFE of Parameter Estimate (E_{max} , EC_{50} , or E_{max}/EC_{50}) Determined at 6, 12, 24, or 48 h Compared with Estimate at 72 h										
Parameter Estimate	Cytochrome P450 Isoform	6 h		12 h		24 h		48 h		
		mRNA	Activity	mRNA	Activity	mRNA	Activity	mRNA	Activity	
E_{max} AFE (<i>n</i>)	CYP1A2	0.33 (7)	0.10 (6)	0.42 (8)	0.35 (7)	0.77 (10)	0.48 (8)	0.89 (10)	0.81 (13)	
	CYP2B6	0.42 (20)	0.10 (7)	0.59 (15)	0.21 (9)	0.64 (18)	0.45 (10)	0.96 (18)	0.90 (13)	
	CYP2C9	0.49 (2)	—	0.84 (3)	—	0.94 (4)	—	1.0 (4)	—	
	CYP3A4	0.29 (9)	0.22 (4)	0.76 (9)	0.30 (9)	0.90 (12)	0.55 (10)	0.97 (12)	0.90 (10)	
	Overall AFE (<i>n</i>)	0.36 (38)	0.13 (17)	0.60 (35)	0.27 (25)	0.76 (44)	0.50 (28)	0.95 (44)	0.87 (36)	
% Within twofold (<i>n</i>)		39 (15)	0 (0)	51 (18)	28 (7)	68 (30)	36 (10)	86 (38)	89 (32)	
	EC_{50} AFE (<i>n</i>)	CYP1A2	0.93 (5)	0.32 (6)	0.64 (8)	1.1 (7)	1.24 (10)	0.56 (7)	0.75 (10)	0.94 (12)
		CYP2B6	1.82 (19)	1.2 (8)	1.99 (12)	1.3 (9)	1.30 (18)	1.0 (11)	1.07 (18)	1.0 (12)
		CYP2C9	2.0 (1)	—	1.1 (3)	ND	2.4 (3)	—	0.70 (4)	ND
		CYP3A4	1.8 (8)	1.1 (3)	2.0 (9)	4.1 (9)	1.6 (12)	2.7 (10)	1.1 (10)	1.5 (10)
Overall AFE (<i>n</i>)		1.64 (33)	0.72 (17)	1.43 (32)	1.89 (25)	1.43 (43)	1.24 (28)	0.96 (42)	1.11 (34)	
% Within twofold (<i>n</i>)		42 (14)	35 (6)	44 (14)	32 (8)	49 (21)	21 (6)	70 (30)	44 (15)	
	E_{max}/EC_{50} AFE (<i>n</i>)	CYP1A2	0.32 (5)	0.34 (4)	0.32 (8)	0.54 (5)	0.35 (10)	0.68 (7)	0.45 (8)	0.84 (11)
		CYP2B6	0.21 (18)	0.083 (8)	0.20 (11)	0.16 (9)	0.52 (17)	0.42 (10)	0.95 (16)	0.94 (13)
		CYP2C9	0.19 (1)	—	0.77 (3)	—	0.43 (3)	—	1.4 (4)	—
		CYP3A4	0.22 (7)	0.071 (2)	0.37 (9)	0.076 (8)	0.55 (12)	0.20 (10)	0.94 (10)	0.60 (10)
Overall AFE (<i>n</i>)		0.23 (31)	0.12 (14)	0.43 (31)	0.16 (22)	0.55 (42)	0.36 (27)	0.99 (38)	0.79 (34)	
% Within twofold (<i>n</i>)		19 (6)	14 (2)	48 (15)	18 (4)	55 (23)	41 (11)	87 (33)	59 (20)	

The PDF and HTML versions of the article have been corrected.

The authors apologize for any inconvenience caused by this error.